Thermo Fisher Scientific Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 30, 2024; comparable period ended April 1, 2023. Amounts are in U.S. dollars. Interim results are unaudited and may not indicate full-year results.
Business context
Thermo Fisher supplies products and services to life sciences, pharmaceutical and biotech, academic and government, industrial, healthcare, and diagnostics markets through four segments: Life Sciences Solutions; Analytical Instruments; Specialty Diagnostics; and Laboratory Products and Biopharma Services.
Financial performance
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $10.345 billion | $10.710 billion | Down 3% |
| GAAP operating income | $1.663 billion | $1.563 billion | Up 6% |
| GAAP operating margin | 16.1% | 14.6% | Up 1.5 points |
| Adjusted operating income (non-GAAP) | $2.278 billion | $2.330 billion | Down 2% |
| Adjusted operating margin (non-GAAP) | 22.0% | 21.8% | Up 0.2 points |
| Net income attributable to Thermo Fisher | $1.328 billion | $1.289 billion | Up 3% |
| GAAP diluted EPS | $3.46 | $3.32 | Up 4% |
| Adjusted EPS (non-GAAP) | $5.11 | $5.03 | Up 2% |
Organic revenue, a non-GAAP measure, declined 4%; acquisitions and currency translation each had no reported impact. Revenue by product and service included consumables of $4.328 billion, instruments of $1.627 billion, and services of $4.390 billion. Gross margin is not separately stated in the filing text.
Cash flow, debt, and liquidity
- Operating cash flow was $1.251 billion, versus $729 million. Free cash flow, a non-GAAP measure, was $908 million, versus $277 million; capital expenditures were $347 million.
- Cash and cash equivalents were $5.499 billion and short-term investments were $1.751 billion at quarter-end, compared with $8.077 billion and $3 million, respectively, at year-end 2023.
- Management reported total debt of $35.608 billion, versus $34.917 billion at December 31, 2023. Current maturities and short-term obligations were $4.451 billion; long-term obligations were $31.157 billion.
- The company had no borrowings under its $5 billion revolving credit facility. Management said cash, operating cash flows, and available borrowing capacity should cover existing business needs for at least the next 24 months.
- Investing cash outflow was $2.030 billion, primarily reflecting $1.758 billion of investment purchases and $347 million of capital expenditures. Financing cash outflow was $1.821 billion, including $3 billion of share repurchases and $135 million of dividends paid.
Changes and segment performance
- Revenue declined primarily due to reduced COVID-19-related demand, lower demand in China and a challenging macroeconomic environment, as well as comparison with strong prior-year instrument shipments. COVID-19 testing product sales fell to $30 million from $140 million.
- Life Sciences Solutions revenue fell 13% to $2.285 billion; segment income was $840 million and margin rose to 36.8%. The company cited lower COVID-related revenue and bioproduction activity, partly offset by productivity improvements and pricing.
- Analytical Instruments revenue fell 2% to $1.687 billion; segment income declined 5% to $400 million and margin fell to 23.7%. Strong electron microscopy growth partly offset prior-year shipment comparisons.
- Specialty Diagnostics revenue was essentially flat at $1.109 billion; segment income rose 5% to $294 million and margin increased to 26.5%, supported by growth in transplant and immunodiagnostics businesses.
- Laboratory Products and Biopharma Services revenue fell 1% to $5.723 billion; segment income declined 6% to $744 million and margin fell to 13.0%. Lower COVID-related vaccine and therapy demand was partly offset by clinical research growth.
- Management attributed improved consolidated GAAP margin chiefly to strong productivity improvements and to lower restructuring charges than in Q1 2023. Mix and strategic investments were offsets. Adjusted operating income declined despite a modest increase in adjusted margin.
Outlook, risks, and unusual items
- Management expects 2024 capital expenditures, net of disposals, of $1.3 billion to $1.5 billion. It expects a 2024 GAAP tax rate of 9% to 11%, an adjusted tax rate of approximately 10.5%, and cash tax payments of approximately $1.60 billion. The filing provides no clear full-year revenue or EPS guidance.
- The company recorded a $240 million tax reserve and associated interest related to potential settlement of international tax audits for tax years 2009–2016. The Q1 tax provision was $281 million, compared with $46 million; the GAAP effective tax rate was 17.7%, versus 3.4%. Management cited the audit-related provision as a principal reason for the increase.
- As of May 3, 2024, the company had identified restructuring actions expected to generate approximately $75 million of additional charges, primarily in 2024. Q1 restructuring and other costs were $29 million, compared with $112 million.
- The proposed acquisition of Olink Holding AB, for approximately $3.1 billion, was expected to close by mid-2024, subject to regulatory approvals, customary conditions, and completion of the tender offer. The company intended to fund it with cash and debt proceeds.
- Risks include continuing weakness in COVID-related demand, macroeconomic and China conditions, customer and government spending, foreign exchange, regulatory and intellectual-property matters, and whether expected acquisition benefits materialize. The company also disclosed environmental remediation and ordinary-course litigation exposures; it said there were no material changes to previously disclosed accruals, while noting that unfavorable outcomes could have a material effect.
Important facts for investors to verify
- Whether revenue trends and demand in China, bioproduction, and COVID-related markets improve or remain weak, and how segment margins respond.
- The resolution and potential financial effect of the international tax audits, including the $240 million reserve and possible changes in tax rates or cash taxes.
- Olink closing timing, regulatory status, financing, integration costs, and expected contribution to results.
- Execution and cost of planned restructuring, along with capital expenditures and cash-flow conversion.
- Debt maturities, refinancing needs, and continued liquidity, particularly alongside acquisitions and share repurchases.
- How non-GAAP measures, including adjusted EPS, adjusted margins, organic growth, and free cash flow, reconcile to GAAP results and should be interpreted.